Abstract: Although febrile complications are rarely encountered after a prostate biopsy procedure, in recent years the number of cases of fatal infection after that have increased along with increases in resistant bacteria. The available biopsy approaches are transrectal and transperineal, with the transrectal approach primarily used. As the invasion path of the puncture needle differs between these approaches, pretreatment and the method of administration of preventive antimicrobial drugs should be separately considered for infection prevention. Recently, the Japanese guidelines for perioperative infection prevention in the field of urology were revised after receiving approval from the Japanese Urological Association. With use of the transrectal approach, attempts have been made to selectively administer prophylactic antibiotics by confirming the presence or absence of resistant bacteria in rectal swab culture results before carrying out a prostate biopsy procedure because of potential problems associated with resistant bacteria in rectal flora. For preventive antibiotics, a single dose of oral quinolone is recommended for patients with low risk, whereas daily administrations of piperacillin/ tazobactam are recommended for those considered to be high risk. In contrast, for the transperineal procedure, a single dose of oral quinolone is recommended as a preventive antibiotic. With both approaches, it is important to empirically administer broad-spectrum antimicrobials when occurrence of a febrile infection after a prostate biopsy procedure is confirmed.
Introduction
Although a prostate biopsy procedure is essential for proper diagnosis of prostate cancer, past reports have noted that the percentage of cases of symptomatic genitourinary tract infection after a prostate biopsy ranges from 0% to 6.3%, 1 of which some were fatal. 2 In nationwide surveys carried out in Europe and North America, the incidence of febrile complications has shown an annual increasing trend along with increases in resistant bacteria. [3] [4] [5] [6] [7] A febrile infection is problematic from the viewpoint of medical economics, because expenses increase as a result of prolongation of hospitalization and treatments carried out for infectious diseases. Thus, various attempts have been made to reduce the incidence of infectious diseases, in particular, measures to deal with the increases in resistant bacteria.
The two approaches available for a prostate biopsy are transrectal and transperineal, though the former is the primary procedure generally used worldwide. In Japan as well, a transrectal procedure is the first choice, whereas transperineal procedures are carried out in approximately 25% of qualified institutions. 8 It is thought that the presence of resistant bacteria in rectal flora affects the onset of infectious diseases after a biopsy, as the device utilized transits through the rectum in a transrectal procedure. In contrast, a transperineal procedure does not involve the rectum, thus it is not affected by resistant bacteria harbored there. Therefore, when considering pretreatment and preventive antibiotic administration methods, it is necessary to consider each approach in an independent manner. The present review was carried out in reference to guidelines previously published as well as more than 1100 articles found in PubMed databases published from 2000 to December 2016 using combinations of key search terms (prostate biopsy, infection).
Does a prostate biopsy procedure require hospitalization?
A prostate biopsy procedure can be commonly carried out on an outpatient basis with local anesthesia. In contrast, in Japan, the procedure is sometimes carried out with lumbar or general anesthesia. As a result, in consideration of possible complications after a biopsy, such as urinary retention, gross hematuria and infection, some practitioners might prefer hospitalization for their patients. Nevertheless, it is important for each patient to be well informed about possible complications after a biopsy carried out either on an outpatient basis or with hospitalization.
Transrectal approach Causative bacteria
Resident intestinal flora should mainly be considered as potential causative bacteria. Escherichia coli, including quinolone resistant and ESBL-producing organisms, [9] [10] [11] [12] [13] are the most frequently encountered pathogens, followed by Klebsiella, 9,10 Enterobacter, 9,11 Citrobacter 9,11 and Proteus, 9 as well as others (Table 1) .
Antibiotics for prevention
A rectal biopsy approach is predominant throughout the world, with the main difference as compared with a transperineal approach being the route of puncture. In recent years, rectal flora resistance to antibiotics has become more serious, and several reports of an increase in infections after a biopsy as a result of greater numbers of resistant bacteria have been presented. [3] [4] [5] [6] [7] As compared with other complications encountered after a prostate biopsy, such as hematuria and urinary retention, the frequency of febrile infections is low. Nevertheless, an optimal antibiotics administration method is important because of the increase in drug-resistant bacteria, as aforementioned, with the most frequently encountered febrile genitourinary infection after a prostate biopsy being acute bacterial prostatitis. Antibiotics are thought to be necessary to prevent such infections, 14 with quinolones, known to be excellent for transition to the prostate, preferentially used. 14, 15 Although the recent increase in quinolone-resistant bacteria is the result of previous inappropriate use of quinolone-based antibacterial drugs, prophylactic quinolone administration is still recommended in Western guidelines. 1, 16 In addition to quinolone antibacterial drugs, the EAU recommends trimethoprim/sulfamethoxazole, 16 whereas the AUA recommends first-to third-generation cephalosporins and aminoglycoside as alternative choices. 17 As for administration duration, the EAU protocol is a single dose for lowrisk cases, extended as appropriate in high-risk cases, whereas the AUA protocol is 24 h for all cases. Furthermore, several studies of quinolone antimicrobial administration duration for prophylaxis before a transrectal prostate biopsy divided their patients into 1-and 3-day groups, though none found a difference in regard to infection rate. [18] [19] [20] [21] The occurrence of infection after a prostate biopsy procedure was also investigated in a multicenter retrospective study by the JRGU. 13 Among patients who underwent a rectal prostate biopsy, 365 were given a single dose (500 mg) and 386 were given multiple doses of levofloxacin. They reported that the number of cases with infection after undergoing a prostate biopsy was three (0.82%) and four (1.04%), respectively, which was not a significant difference. These results suggest that when quinolone antibiotics are given as a single prophylactic administration before carrying out a transrectal prostate biopsy, a sufficiently high dose is required.
The Japanese guidelines for prevention of perioperative infections in the urological field, initially presented in 2006, refer to use of preventive antibiotics for patients undergoing a prostate biopsy. 22 In the revision published in 2015, the recommended types and duration of antibiotics are also noted. 23 More than 10 years ago, a single 500-mg dose of oral levofloxacin was reported to be effective and safe for low-risk patients. 24 As noted above, a retrospective multicenter study carried out in Japan found no significant difference in the infection rate between patients given a single dose of quinolone antibiotics as compared with those administered for ≥2 days, at least in low-risk cases. 13 As in Western guidelines, those presented in Japan note that a single administration of quinolone antibiotics is recommended. However, in the present era of increased quinolone-resistant bacteria, prevention of infection with only a single antibacterial administration of quinolone seems to be difficult.
The rates of infection incidence were reported to decrease with use of aminoglycoside antibiotics [25] [26] [27] and cephalosporins 28, 29 in combination with oral quinolone antibacterial drugs. In contrast, no difference in infection rate was found when those were combined with aminoglycoside drugs, though concurrent use is considered to be one of the options (Fig. 1) . 30 In our previous study carried out in Japan in 2011 of transrectal biopsy cases, oral quinolone and intravenous cephalosporin were used in 32.6% and 23.3%, respectively. 8 Although EAU and AUA guidelines recommend trimethoprim/sulfamethoxazole or first-to third-generation cephalosporins and aminoglycoside as alternative choices, they are not recommended in the JUA guidelines, because evidence is insufficient. In order to confirm the effectiveness of PIPC/ TAZ, a multicenter collaborative research was carried out at JRGU between 2009 and 2012. Of 442 patients who received preventive antibacterial administration of PIPC/TAZ at 4.5 g twice a day before undergoing a transrectal biopsy procedure, a febrile UTI appeared in just two patients (0.45%). In contrast, of 160 patients who received a single dose of PIPC/ TAZ at 4.5 g, a febrile UTI developed in four. All cases of febrile UTI in that report also had a prostate volume of ≥75 mL, diabetes mellitus, prior steroid administration, severe Others dysuria (International Prostate Symptom Score of ≥20, peak flow rate ≤12 mL/s, postvoid residual urine volume ≥100 mL) and an immunocompromised state. When the incidence of febrile UTI was examined only in patients in the high-risk group, a single administration as a prophylactic antibacterial agent was shown to be insufficient in four patients (4.55%) of 88 who received a single dose as compared with two patients (2.3%) of 87 who received the administration twice a day. These findings confirmed the recommendations in the 2015 Japanese guidelines for administration twice a day for 4.5 days in high-risk patients (Fig. 1) . 31 However, PIPC/TAZ, a broad-spectrum intravenous antibiotic treatment, should only be used for patients with high risk.
Non-antibiotic prevention procedures

Rectal culture
Several reports have noted that the presence of quinoloneresistant bacteria is a risk factor for occurrence of infectious diseases after a prostate biopsy procedure. [32] [33] [34] [35] Thus, it is questionable whether quinolone antibiotics can be overwhelmingly effective for prevention in patients who undergo a transrectal prostate biopsy. It is known that approximately 20% of the bacterial flora in the rectum of patients undergoing a biopsy is composed of quinolone-resistant E. coli, which is especially problematic for a transrectal procedure, as the biopsy needle transits through the rectum. In Korea, a country in the same part of Asia as Japan, the frequency of quinolone-resistant bacteria is 26.7%, which is greater than that reported in Western countries. 36 Furthermore, a prospective study carried out at a single facility in Thailand found that when a rectal swab was carried out before a prostate biopsy procedure, 92.3% of the Gram-negative bacilli detected were quinolone-resistant bacteria. 9 Taylor et al. compared the incidence of infectious disease after a rectal biopsy between 112 patients who underwent a rectal swab culture before the procedure and 345 who did not. 32 Their results suggested that targeted antimicrobial prophylaxis reduces the incidence of infectious complications after a transrectal biopsy and is also beneficial in regard to medical economics, and they recommended the use of a rectal swab culture before that procedure. In their study, a targeted antimicrobial prophylaxis was administered to 22 (19.6%) of the 112 patients in whom quinolone-resistant bacteria were observed and who underwent rectal swab culturing, whereas 90 patients (80.4%) who were quinolone sensitive received an administration of quinolone as an oral antimicrobial agent, with only one case of infection observed. Meanwhile, nine (2.6%) of the 345 patients who did not undergo rectal swabbing developed an infection. The cost of targeted and empirical prophylaxis procedures per person in 100 men undergoing a prostate biopsy was calculated to be $1346 and $5598, respectively. Cost-effectiveness analysis showed that targeted prophylaxis yielded a cost savings of $4499 per post-biopsy infectious complication. The effectiveness of carrying out a susceptibility test of the intestinal microbial community before a rectal biopsy has been shown, and there is a possibility that it might become a mainstream procedure in the future.
Along with the increase in quinolone-resistant E. coli, European guidelines 16 listed rectal swabbing as an option for the first time in 2014, and a number of studies have noted its utility. 32, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Rectal screening before a biopsy examination is not covered by national health insurance in Japan, and is extremely difficult to carry out for most cases. Therefore, selection of patients harboring quinolone-resistant bacteria is a key issue. Recent reports have noted that a risk factor for generation of quinolone-resistant bacteria is a history of oral quinolone treatment. 43, 44, 47, 48 Furthermore, several reports have shown that antimicrobial use within the past 3-to 6-month period is significantly associated with the presence of resistant bacteria in rectal flora.
9,43,48-50
Currently, it is considered desirable to utilize rectal swabs and drugs adapted to sensitivity, or avoid the use of quinolone oral antimicrobials and change to other agents when a history of quinolone oral history has been confirmed. A flow chart of antimicrobial prophylaxis in patients undergoing a transrectal/ transperineal biopsy procedure is presented in Figure 1 .
Rectal disinfection
Rectal disinfection with povidone-iodine before a transrectal biopsy has been reported to reduce the incidence of biopsyrelated infections. 41, 51 In that latter study, AbuGhosh et al. into the disinfection with povidone-iodine (n = 421) and nondisinfection (n = 444) groups. They found that the incidence of infections was 2.6% and 4.5%, respectively, which was not significantly different between the groups, though performance of rectal disinfection decreased the incidence of infection by 42%. 51 In addition, a multicenter retrospective study of the incidence of infectious disease in 4358 transrectal prostate biopsy procedures carried out at universities and related institutions belonging to the JRGU in 2011 found that rectal disinfection before the biopsy was a significant factor for reducing the occurrence of infection (P = 0.0001). 13 Based on these reports, it is considered that rectal disinfection with povidone-iodine before performance of a transrectal biopsy reduces the risk of infection after the examination.
Repeat biopsy
Liss et al. compared quinolone-resistant colonization between initial and second prostate biopsy procedures, and found no significant difference regarding the rate of quinolone resistance (16.3% vs 18.6%, P = 0.78). 12 Loeb et al. also reported that a repeat biopsy procedure itself was not associated with an increased risk of infectious complications as compared with the initial biopsy. 52 In contrast, Ehdaie et al. reported that the probability of a post-biopsy infection in patients who had undergone one or two previous biopsies was 2%, whereas that in those who had five or more biopsies was 15%. 53 Also, Ozden et al. reported that a greater rate of acute prostatitis was observed in their repeat biopsy group than in patients who had undergone a prostate biopsy procedure for the first time (6.8% vs 1.3%). 54 Taken together, it is considered that a repeat biopsy might be associated with an increased risk of infectious complications, though consensus has not been reached.
Biopsy core and needle gauge
Previous studies have found no significance in regard to the number of biopsy specimens 21, 55 or thickness of the puncture needle 56 in regard to occurrence of a post-biopsy infection.
Formalin disinfection of biopsy needle
Issa et al. reported that formalin disinfection of the puncture needle led to decreased rates of infection by quinolone-resistant bacteria. 57 Although their study is very interesting, there is concern regarding the toxicity of formalin. However, should its safety in vivo be guaranteed, there is a possibility of this becoming a mainstream procedure.
Transperineal approach Antibiotics for prevention
The infection rate for a transrectal biopsy procedure has been reported to be not different as compared with that for a transperineal procedure, [58] [59] [60] whereas other reports have noted that the infection rate for the latter is low. 61, 62 In contrast, some have recommended quinolone-based antimicrobial prophylaxis. [63] [64] [65] Taken together, there is currently scant evidence showing that antibiotics are not required.
In both Europe and the USA, a transrectal biopsy is the primary procedure used, while evidence related to use of a transperineal method is lacking, thus details are not specified in Western guidelines. Nevertheless, a single dose of antibiotics is recommended for a transperineal procedure in the EAU, whereas that is not described in the AUA.
In a retrospective study carried out in Japan, we compared 335 patients who received a single dose and 217 who received multiple doses of LVFX at 500 mg as single agent therapy for a transperineal prostate biopsy. 13 The number of occurrences of infectious disease after the procedure was one in each group (0.30% vs 0.46%), which was not a significant difference. Therefore, in the Japanese guidelines, antimicrobial prophylaxis with a single administration of quinolone oral antibiotics is recommended for patients undergoing a transperineal biopsy (Fig. 1) . 23 In our previous study carried out in Japan in 2011, oral quinolone and intravenous cephalosporin administrations were found to be used in 37.1% and 36.0%, respectively, of transperineal biopsy cases. 8 
Prevention without antibiotics
In a retrospective study, we found that the presence or absence of enema or rectal disinfection use before a transperineal biopsy procedure was not a risk factor for onset of infectious disease. 13 As exposure of intestinal bacteria from the perineum is unlikely in those cases, it is considered unnecessary to treat the intestinal tract in the same manner as in transrectal biopsy cases. Nevertheless, placement of a urethral catheter before a transperineal biopsy was found to be a significant risk factor for occurrence of infection in that study (P < 0.001). In cases with urinary catheter placement, there is a high rate of pyuria and bacterial urine, which might contribute to infection onset. Therefore, a urine culture should be carried out in cases with pyuria before the examination, with priority given to those with positive findings or selection of a susceptible drug as an infection prevention antibiotic. It is presumed that infections after a transperineal biopsy will decrease if these precautions are used. The usefulness of a template biopsy has also been pointed out in recent studies. 66, 67 As for the number of biopsies, there are reports that a greater number is not related to an increase in the risk of infection. [68] [69] [70] As for diabetes, which is considered to be a risk factor in transrectal, 11, 32 but not transperineal 13, 71 procedures. A recent AUA white paper included a description that recommends choosing a transperineal approach in high-risk cases, 72 as well as in patients who have previously undergone a negative transrectal biopsy. 73 Smith et al. reported the same findings even in transperineal biopsy patients who received local anesthesia. 74 In addition, a recent review noted that there was no significant difference in the infection rate between rectal and perineal approaches, whereas the transperineal approach was mentioned due to the fact that a transperineal biopsy procedure poses a lower risk for infection, because it avoids rectal flora seeding of the prostate gland. 75 There is also an increasing number of reports recommending a transperineal prostate biopsy, thus it is expected that the number of institutions using that approach will increase in the near future. 6, 66, 76 Sepsis and mortality Septic shock rarely occurs in patients after a prostate biopsy procedure. [77] [78] [79] In a retrospective study of 212 065 biopsies reported that the rate of sepsis after a prostate biopsy was 0.07%. 61 However, an increase in infectious diseases caused by ESBL-producing bacteria has recently been reported. 54, 80, 81 Notably, a febrile UTI after the examination can be serious and life threatening, thus an urgent response is necessary. Williamson et al. found that 17 (36%) of 47 cases with E. coli bacteremia development after a transrectal biopsy received inappropriate empiric therapy, of which 12 (25%) were regarded as serious and requiring admission to the intensive care unit. 82 Furthermore, they concluded that empiric therapy for fever after the examination requires a broad-spectrum antimicrobial drug administration. In addition, Tumbarello et al. reported that improper empiric therapy for bacteremia caused by E. coli is related to increased mortality. 80 The mortality rate after a biopsy has been reported to be 0.09%. 4 
Treatment for biopsy-related infection
Administration of carbapenems or PIPC/TAZ has been reported to be effective for fever that develops after a prostate biopsy procedure. 47, 54, 83 Whenever an infection develops, urine and blood cultures should always be carried out before administration of antibacterial drugs, with broad-spectrum antimicrobials known to be effective for quinolone-resistant bacteria and ESBL-producing bacteria administered.
Surveillance
Infections after a prostate biopsy procedure have been reported to be increasing, whereas other complication frequencies have not increased. [3] [4] [5] [6] [7] Batura et al. noted that construction of a nationwide surveillance system for monitoring is important. 76 A system of surveillance of infections after a prostate biopsy procedure has not been established in Japan. However, as the numbers of resistant bacteria have been increasing in recent years, such a nationwide system should be established in order to monitor infection rates and causative bacteria after prostate biopsy procedures are carried out.
Conclusion
Although is impossible to completely eliminate the occurrence of infectious diseases after a biopsy of the prostate because of recent increases in resistant bacteria, it is necessary to be aware of the potential risk and judge individual cases, and then select appropriate pretreatment including antibiotics as necessary.
